Finland's Orion eyes US sales boost with blockbuster prostate cancer drug
By Anne Kauranen
HELSINKI, Sept 26 (Reuters) -Finnish drugmaker Orion ORNBV.HE wants to boost sales in the United States on the back of the success of its prostate cancer drug Nubeqa, which it is developing jointly with German partner Bayer BAYGn.DE, Orion's chief executive Liisa Hurme told Reuters.
The two companies announced on Thursday that sales of Nubeqa have been worth more than a billion euros this year, making it Orion's first "blockbuster" product, and that Bayer is seeking approval from U.S. authorities to expand its use to a new patient group.
Nubeqa, also known as darolutamide, is Bayer's third best selling drug globally with sales growing most rapidly in the U.S., Hurme said.
That encouraged Orion to establish a research centre in the U.S. last year, with an eye on growth opportunities in a country that accounts for roughly half of the world's drug market, Hurme said.
"We are in the U.S. in order to develop our own innovations in that market ourselves," she said, referring to Orion's ODM-111 molecule for pain treatment and Orion's cooperation with U.S. based drugmaker Merck & Co MRK.N in the development of opevesostat, used against metastatic castration-resistant prostate cancer, among other products.
"Pain is highly undertreated and especially in the U.S., the use of opiates is a major problem," she added, referring to the expansion of drug misuse.
Bayer said it was submitting an application to the U.S. Food and Drug administration for a third indication for darolutamide to be used in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, following a successful phase III trial.
Reporting by Anne Kauranen; Editing by Kirsten Donovan
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
